// App-Quantinova.ai

: Fevipiprant reduces airway smooth muscle mass in asthmatics via PGD2 receptor antagonism

Researchers

Presenter

  • Ruth Saunders

Principal Investigators

  • Himanshu Kaul

  • Rachid Berair

  • Amisha Singapuri

  • Igor Chernyavsky

  • Latifa Chachi

  • Michael Biddle

  • Amanda Sutcliffe

  • Marie Laurencin

  • Gerald Bacher

  • Michelle Bourne

  • Ian D. Pavord

  • Andrew J. Wardlaw

  • Salman H. Siddiqui

  • Richard Kay

  • Bindi S. Brook

  • Rod Smallwood

  • Chris E. Brightling

Medical Centers

  • University of Leeds, Leeds, United Kingdom

  • University of Manchester, Manchester, United Kingdom

  • Novartis AG, Basel, Switzerland

  • Novartis Pharmaceuticals Corporation East Hanover NJ United States

  • University of Oxford, Oxford, United Kingdom

  • University of Nottingham, Nottingham, United Kingdom

  • University of Sheffield, Sheffield, United Kingdom

Locations

  • United Kingdom

  • Switzerland

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Prostaglandin D2

Drug/Treatment

  • Fevipiprant

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved